When Elevidys Isn't an Option, There Are Other Treatments

If your child has Duchenne muscular dystrophy (DMD) and you've been told that Elevidys (Delandistrogene Moxeparvovec-rokl) isn't accessible right now — whether due to insurance denials, the 2025 shipment pause, eligibility restrictions, or treatment center capacity — you're probably wondering what other options exist.

The good news is that while Elevidys is the only FDA-approved gene therapy for DMD, there are several other approved treatments that can help manage the condition. Let's walk through what Elevidys does, why you might not be able to access it, and what alternatives are available.

What Is Elevidys and How Does It Work?

Elevidys is a gene therapy made by Sarepta Therapeutics. It uses an adeno-associated virus (AAVrh74) to deliver a shortened version of the dystrophin gene — called micro-dystrophin — directly to muscle cells. In patients with DMD, the full-length dystrophin gene is mutated and doesn't produce functional protein, which leads to progressive muscle weakness and deterioration.

By introducing micro-dystrophin, Elevidys aims to partially restore the missing protein and stabilize muscle cell membranes. It's given as a single, one-time IV infusion at a specialized center and costs approximately $3.2 million.

The treatment is currently approved only for ambulatory patients aged 4 and older with a confirmed DMD gene mutation. The non-ambulatory indication was withdrawn in 2025 following reports of fatal liver injury.

For more details, see our article on how Elevidys works.

Why You Might Not Be Able to Access Elevidys

There are several common reasons families can't access Elevidys right now:

• Insurance denial — The $3.2 million cost means extensive prior authorization is required, and initial denials are common
• Eligibility restrictions — Only ambulatory patients aged 4+ with confirmed DMD mutations are eligible; patients with exon 8 or 9 deletions are excluded
• Limited treatment centers — Only specialized neuromuscular centers can administer gene therapy
• Supply and logistics — Weight-based kits must be specifically ordered and matched to the patient
• Safety concerns — Some families and doctors may be cautious due to the Boxed Warning for liver failure

Alternative Treatments for Duchenne Muscular Dystrophy

1. Deflazacort (Emflaza)

Deflazacort, sold under the brand name Emflaza, is a corticosteroid specifically approved by the FDA for the treatment of DMD in patients aged 2 years and older. It is one of the most widely used treatments for DMD and is typically the first-line medication prescribed.

How it works: Deflazacort reduces inflammation and slows the rate of muscle deterioration. While it doesn't address the underlying genetic cause of DMD like Elevidys does, it has been shown to help maintain muscle strength and function for longer.

Key facts:

• Taken daily as an oral tablet or suspension
• Available in generic form, which is more affordable
• Common side effects include weight gain, increased appetite, and cushingoid appearance
• Long-term use can lead to bone density loss and growth suppression

2. Eteplirsen (Exondys 51)

Eteplirsen, branded as Exondys 51, is an exon-skipping therapy made by Sarepta Therapeutics (the same company that makes Elevidys). It was the first exon-skipping drug approved for DMD.

How it works: Eteplirsen is designed to skip exon 51 during the processing of dystrophin pre-mRNA. This allows the body to produce a shorter but partially functional version of dystrophin. It's only effective for patients whose DMD mutation is amenable to exon 51 skipping (approximately 13% of DMD patients).

Key facts:

• Administered as a weekly IV infusion
• Approved under accelerated approval; clinical benefit not fully confirmed
• Generally well-tolerated
• Cost is approximately $300,000-$400,000 per year

3. Casimersen (Amondys 45)

Casimersen, sold as Amondys 45, is another exon-skipping therapy from Sarepta. It targets exon 45, making it suitable for a different subset of DMD patients.

How it works: Like Eteplirsen, Casimersen helps the body skip a specific exon during dystrophin mRNA processing, allowing production of a truncated but partially functional dystrophin protein. It's effective only for patients with mutations amenable to exon 45 skipping (approximately 8% of DMD patients).

Key facts:

• Weekly IV infusion
• Approved under accelerated approval
• Similar tolerability profile to other exon-skipping therapies

4. Viltolarsen (Viltepso)

Viltolarsen, marketed as Viltepso, is an exon-skipping therapy made by NS Pharma. It targets exon 53, making it an option for yet another subset of DMD patients.

How it works: Viltolarsen skips exon 53 during dystrophin mRNA processing. It's suitable for approximately 8% of DMD patients whose mutations are amenable to exon 53 skipping.

Key facts:

• Weekly IV infusion
• Has shown increases in dystrophin protein levels in clinical studies
• Generally well-tolerated with injection site reactions being the most common side effect

How to Choose the Right Alternative

The right alternative depends on several factors:

• Your child's specific genetic mutation — Exon-skipping therapies only work for specific mutations
• Ambulatory status — Some treatments are more appropriate at different stages of the disease
• Current medications — Most DMD patients are already on corticosteroids
• Insurance coverage — Coverage varies by treatment and plan

Your child's neurologist or neuromuscular specialist is the best person to help determine which alternatives make sense. For help finding a specialist, see our article on finding a doctor who can help with DMD treatment.

Don't Give Up on Elevidys

If Elevidys is the right treatment for your child, keep pursuing access even while using alternative treatments. Many of the barriers — insurance denials, treatment center waitlists — can be overcome with persistence and the right support.

• Contact SareptAssist at 1-888-727-3782 for help with insurance and access
• Use Medfinder to track Elevidys availability
• Read our shortage update for the latest information

Final Thoughts

While Elevidys represents a breakthrough in DMD treatment, it's not the only option. Corticosteroids like Deflazacort remain a cornerstone of DMD management, and exon-skipping therapies offer targeted treatment for patients with specific mutations. Work closely with your child's medical team to find the best combination of treatments while continuing to pursue Elevidys access if appropriate.

For more information, read our guides on what Elevidys is, saving money on treatment, and drug interactions to be aware of.